PANoptosis in the pathogenesis of myelodysplastic syndromes
Molecular Oncology · 2026-11 · 20 (11) · 2584-2610
DOI: 10.1002/1878-0261.70309 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 24.07.2026. Verfasst von Rohit Thalla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, IL, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Apoptosis, Necroptosis. Die Arbeit nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Cancer Prevention, National Cancer Institute, NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) are a heterogeneous group of pre‐leukemic diseases marked by ineffective bone marrow (BM) hematopoiesis, peripheral cytopenia, morphologic dysplasia, and an increased risk of leukemic transformation. Increased programmed cell death (PCD) of hematopoietic stem/progenitor cells (HSPCs) and its associated inflammatory BM microenvironment have been speculated to be one of the major causes of ineffective hematopoiesis. PANoptosis is a collective term for three types of PCD: pyroptosis, apoptosis, and necroptosis. All three are mediated by a very large protein complex called a PANoptosome, composed of the key mediators of the three types of PCD. We reported that the diseased cells in MDS with genetic abnormalities, especially spliceosome mutations, show aberrant hypersensitivity to PANoptotic stimuli. Our study suggests that increased PANoptosis of BM HSPCs is one of the reasons for the ineffective hematopoiesis in MDS patients, and targeting PANoptosis may be a novel treatment strategy for MDS. Here we summarize recent advances in research into PANoptosis and discuss the potential role of PANoptosis in the pathogenesis of MDS. We discuss the potential mechanisms for targeting PANoptotic pathways to treat MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, IL, USA.
- Department of Cancer Biology, Loyola University Chicago Medical Center, Maywood, IL, USA.
- Departments of Biology and Molecular/Cellular Physiology, Loyola University Chicago, Maywood, IL, USA.
ORCID-Profile: Jiwang Zhang
Förderung
- Division of Cancer Prevention, National Cancer Institute
- NHLBI NIH HHS
- NCI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Thalla, R., Lamichhane, J., Lewis, C., Breslin, P., & Zhang, J. (2026). PANoptosis in the pathogenesis of myelodysplastic syndromes. Molecular Oncology, 20(11), 2584-2610. https://doi.org/10.1002/1878-0261.70309
Vancouver
Thalla R, Lamichhane J, Lewis C, Breslin P, Zhang J. PANoptosis in the pathogenesis of myelodysplastic syndromes. Molecular Oncology. 2026;20(11):2584-2610. doi:10.1002/1878-0261.70309
BibTeX
@article{Thalla2026,
author = {Thalla, Rohit and Lamichhane, Jyoti and Lewis, Cameron and Breslin, Peter and Zhang, Jiwang},
title = {PANoptosis in the pathogenesis of myelodysplastic syndromes},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2584--2610},
doi = {10.1002/1878-0261.70309}
}
EUVIMED